Your browser is no longer supported. Please, upgrade your browser.
GALT [NASD]
Galectin Therapeutics Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own11.60% Shs Outstand57.08M Perf Week-16.41%
Market Cap127.50M Forward P/E- EPS next Y-0.69 Insider Trans-1.39% Shs Float40.56M Perf Month-6.81%
Income-23.60M PEG- EPS next Q-0.17 Inst Own17.80% Short Float11.77% Perf Quarter-1.79%
Sales- P/S- EPS this Y-7.10% Inst Trans2.71% Short Ratio2.78 Perf Half Y-20.65%
Book/sh0.38 P/B5.76 EPS next Y-27.90% ROA-63.30% Target Price- Perf Year27.33%
Cash/sh0.47 P/C4.70 EPS next 5Y- ROE-74.60% 52W Range1.70 - 3.85 Perf YTD-2.23%
Dividend- P/FCF- EPS past 5Y13.90% ROI- 52W High-30.78% Beta1.98
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low56.76% ATR0.27
Employees6 Current Ratio5.50 Sales Q/Q- Oper. Margin- RSI (14)58.21 Volatility14.51% 11.59%
OptionableYes Debt/Eq0.00 EPS Q/Q-13.20% Profit Margin- Rel Volume6.23 Prev Close2.19
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.72M Price2.66
Recom2.00 SMA2018.46% SMA5015.74% SMA2004.58% Volume9,530,206 Change21.69%
Aug-13-20Reiterated H.C. Wainwright Buy $9 → $12
Feb-13-19Initiated B. Riley FBR Buy $11
Dec-07-17Reiterated H.C. Wainwright Buy $6 → $10
Nov-28-17Reiterated H.C. Wainwright Buy $3.50 → $6
Oct-19-17Initiated ROTH Capital Buy
Mar-30-17Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-03-16Downgrade FBR & Co. Outperform → Mkt Perform $12 → $2
Sep-29-16Downgrade H.C. Wainwright Buy → Neutral $1.50
Sep-28-16Downgrade ROTH Capital Buy → Sell
Mar-28-16Resumed H.C. Wainwright Buy $8
Sep-21-15Initiated H.C. Wainwright Buy $7
Aug-01-14Downgrade Aegis Capital Buy → Hold
Jul-30-14Reiterated MLV & Co Buy $27 → $16
Jul-29-14Reiterated MLV & Co Buy $27 → $15
Apr-02-14Reiterated MLV & Co Buy $20 → $27
Feb-10-14Reiterated Aegis Capital Buy $16 → $32
Jan-09-14Reiterated Aegis Capital Buy $10 → $16
Dec-03-13Initiated MLV & Co Buy $20
Aug-19-13Reiterated Aegis Capital Buy $7 → $10
Apr-19-21 08:00AM  
Apr-15-21 09:00AM  
Apr-14-21 08:28AM  
Apr-13-21 07:01PM  
Apr-06-21 08:00AM  
Mar-31-21 08:00AM  
Mar-08-21 08:00AM  
Mar-04-21 08:00AM  
Jan-31-21 02:28AM  
Jan-19-21 11:15AM  
Dec-11-20 08:00AM  
Dec-04-20 04:17PM  
Dec-01-20 08:00AM  
Nov-09-20 08:00AM  
Nov-02-20 08:02AM  
Oct-12-20 08:11AM  
Oct-06-20 03:30PM  
Sep-29-20 12:00PM  
08:52AM  
Sep-22-20 08:04AM  
Sep-10-20 08:00AM  
Sep-09-20 11:46AM  
Sep-02-20 08:00AM  
Aug-10-20 08:00AM  
Aug-03-20 12:48PM  
Jun-30-20 09:05AM  
08:00AM  
Jun-04-20 09:48PM  
May-22-20 08:17AM  
May-11-20 08:00AM  
May-04-20 08:37AM  
Apr-30-20 09:00AM  
Apr-02-20 08:04AM  
Mar-16-20 08:00AM  
Feb-20-20 08:00AM  
Feb-05-20 04:11PM  
Feb-04-20 08:04AM  
08:00AM  
Dec-20-19 06:38PM  
Dec-09-19 08:00AM  
Dec-05-19 12:06PM  
Nov-26-19 08:00AM  
Nov-18-19 04:10PM  
Nov-12-19 08:00AM  
Nov-11-19 09:47AM  
Nov-05-19 08:00AM  
Oct-28-19 08:39AM  
Sep-17-19 08:00AM  
Sep-11-19 10:13AM  
Aug-27-19 03:21PM  
10:21AM  
09:00AM  
Aug-09-19 08:00AM  
Aug-07-19 11:20AM  
11:15AM  
Aug-06-19 10:51AM  
Aug-05-19 08:05AM  
May-28-19 09:05AM  
May-27-19 08:44AM  
May-23-19 05:30PM  
May-10-19 08:05AM  
08:00AM  
Apr-15-19 08:00AM  
Apr-02-19 08:00AM  
Mar-22-19 10:19AM  
Mar-06-19 11:34AM  
08:03AM  
08:02AM  
08:00AM  
Feb-26-19 07:25AM  
Feb-25-19 08:00AM  
Feb-13-19 03:36PM  
09:53AM  
Feb-04-19 09:27AM  
Feb-01-19 10:07AM  
Jan-30-19 09:30AM  
Jan-15-19 08:00AM  
Dec-25-18 01:28PM  
Dec-20-18 08:30AM  
Nov-27-18 08:15AM  
Nov-19-18 09:19AM  
Nov-13-18 08:00AM  
Nov-05-18 08:37AM  
08:00AM  
Oct-15-18 10:22AM  
08:00AM  
Oct-11-18 07:30AM  
Sep-26-18 03:21PM  
Sep-21-18 10:43AM  
08:00AM  
Sep-20-18 08:25AM  
08:00AM  
Sep-18-18 08:53AM  
Aug-31-18 02:46PM  
Aug-21-18 11:27AM  
Aug-20-18 08:42AM  
Aug-14-18 08:00AM  
Aug-03-18 07:30AM  
Jul-26-18 08:57AM  
Jul-11-18 07:45AM  
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FREEMAN KEVIN DDirectorApr 05Buy2.045,00010,20030,000Apr 06 09:00 AM
10X Fund, L.P.10% OwnerApr 01Sale2.1610,00021,6006,316,440Apr 05 01:48 PM
10X Fund, L.P.10% OwnerMar 01Sale2.3110,00023,1006,326,440Mar 04 04:06 PM
10X Fund, L.P.10% OwnerFeb 02Sale2.0410,00020,4006,336,440Feb 05 10:47 AM
AMELIO GILBERT FDirectorJan 11Sale2.1760,000130,20060,614Jan 19 09:00 AM
10X Fund, L.P.10% OwnerJan 04Sale2.2310,00022,3006,346,440Jan 05 05:36 PM
10X Fund, L.P.10% OwnerOct 13Sale2.9710,00029,7006,356,440Oct 15 05:03 PM
Uihlein Richard EDirectorSep 04Buy2.5510,00025,5007,893,191Sep 09 08:00 AM
FREEMAN KEVIN DDirectorSep 04Buy2.575,00012,84825,000Sep 09 08:00 AM